Tag Archive: #AMC

  1. EAVI2020 at the Keystone Symposia on HIV vaccines, 26-31 March 2017

    Leave a Comment

    EAVI2020’s partner institutions presented the latest research on HIV vaccines at the Keystone Symposia on HIV vaccines.

    As part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation, the HIV vaccines series took place on the 26-31 March 2017 in Colorado, USA.

    Despite great progress in preventing and treating HIV, new infections continue to plague communities around the world, and the need for an HIV vaccine is as urgent as ever. Several large cohorts of HIV-infected individuals have enabled tremendous advances over the past five years in understanding immune responses to natural HIV infection. These advances have included the isolation of broad and potent anti-HIV antibodies, defining their developmental pathways, the generation of native-like Env trimers for immunization, and high-resolution structures of the envelope glycoprotein in complex with bnAbs. By 2017, many of these discoveries will have enabled new concepts to transition into human clinical trials, including passive monoclonal antibody therapy and novel immunization approaches. These platforms, incorporating improved technology for monitoring immune responses, will drive major advances in the vaccine field. This HIV Vaccines meeting will present the latest results from human clinical studies, along with the cutting-edge basic science behind such trials to highlight approaches that may lead to an HIV vaccine, and also reveal the molecular underpinnings of B and T cell-mediated immunity.

    EAVI2020 at the Keystone Symposia

    EAVI2020 partners gave presentations on the latest research developments under EAVI2020 on topics like DNA Vaccination for Experimental Medicine Trials of HIV Vaccines (R. Shattock, Imperial), Inducing HIV-1 Neutralizing Antibodies with Native-Like Envelope Trimers (R. Sanders, AMC), Individualized Profiling of Germline V Genes and Application to Env Trimer Immunogenicity Studies in NHPs (G. Karlsson Hedestam, Karolinska Institutet) and ADCC and Beyond (S. Kent, University of Melbourne).

    EAVI2020’s PhD student Yoann Aldon also gave a poster presentation on HIV vaccines management.

    More information

    Full programme and for more information on the Keystone Symposia on HIV vaccines.

    For more information about EAVI2020, please contact us.

    Gunilla Karlsson Hedestam talking in front of a digital projection Rogier Sanders talking behind a lectern

    G. Karlsson Hedestam and R. Sanders.
  2. Marit van Gils wins the Beijerinck Premium award from the Royal Dutch Academy of Science.

    Leave a Comment

    The Beijerinck Premium is intended to encourage virology research and is awarded every two years.

    Marit van Gils is a post-doc researcher at Academisch Medisch Centrum and is part of the team working in EAVI2020. This award is given to young post-doc researchers in recognition of outstanding virus-related research at a Dutch scientific organisation.
    The ceremony will take place on the 3rd March 2017.

    More information
    For more information please go to the Beijerinck Premium’s website.

  3. Presentations from EAVI2020 partners at the 2016 Keystone Symposia on HIV Vaccines are available online!

    Leave a Comment

    The Global HIV Vaccine Enterprise in collaboration with Keystone Symposia organized an ePanel discussion and series of SciTalks presentations that brought together key experts in the HIV prevention vaccine field.

    The ePanel and SciTalks addressed a broad range of topics pertinent to state-of-the-art HIV vaccine research. As part of the Global HIV Vaccine Enterprise eAccess Meetings initiative, videos of several presentations recorded onsite at the 2016 Keystone Symposia on HIV Vaccines are available.


    EAVI2020 – present at the 2016 Keystone Symposia on HIV Vaccines

    The Keystone Symposia highlighted cutting-edge scientific developments and challenges in the field in 90-minute sessions that included SciTalk presentations by EAVI2020 Partners:

    Professor Tomas Hanke, from the University of Oxford, presented “A novel conserved-region T-cell mosaic vaccine with very high global coverage of HIV-1 variants is recognized by protective responses in chronic untreated infection” and his presentation is available as a webcast.

    Dr Marit van Gils, from Academisch Medisch Centrum, received the New Investigator Award at HIVR4P and presented “A broadly neutralizing antibody from an elite neutralizer, targets a novel site at the gp120-gp41 interface”. Her presentation is available as a webcast.

    More information

    eAccess Meetings past presentations.
    For more information about EAVI2020, please contact us.

  4. Marit van Gils selected for the New Investigator Award, HIVR4P conference.

    Leave a Comment

    Marit van Gils, who is part of the Academisch Medisch Centrum‘s team involved in EAVI2020, has been selected as one of eight New Investigator Award recipients of the HIV Research for Prevention 2016: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P) conference.

    HIVR4P, the first global scientific conference focused exclusively on biomedical HIV prevention research, will be held from 17–21 October in Chicago, Illinois, USA. She will present her work  ‘Potent HIV Neutralizing Antibodies Elicited by BG505 SOSIP Trimer Immunization in Rhesus Macaques as a Starting Point for Iterative Vaccine Design’ during an oral presentation.

    Abstract

    Potent HIV Neutralizing Antibodies Elicited by BG505 SOSIP Trimer Immunization in Rhesus Macaques as a Starting Point for Iterative Vaccine Design

    Author(s): Marit van Gils1, Jelle van Schooten1, Christopher Cottrell2, Gabriel Ozorowski2, Robert Morpurgo1, Devin Sok2, Dennis Burton2, John Moore3, Andrew Ward2, Rogier Sanders1

    Institute(s): 1Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2The Scripps Research Institute, San Diego, United States, 3Weill Cornell Medical College, New York, United States

    Background: Broadly neutralizing antibodies (bnAbs) isolated from HIV-1 infected individuals have revealed that the human immune system is capable of eliciting bnAbs that can protect against infection, as confirmed in macaque challenge studies. The BG505 SOSIP trimer has been chosen as the envelope glycoprotein most related to the unmutated common ancestor of the bnAb PG9/PG16 patient. This soluble native-like protein was capable of eliciting neutralizing serum responses against the homologous (Tier-2) virus however, how to broaden the response to target heterologous Tier-2 viruses is still unclear.

    Methods: Immunogen-specific IgG+ B cells from 2 BG505 SOSIP immunized rhesus macaques over time were single-cell sorted to obtain monoclonal antibodies (mAbs). These antibodies were further characterized for their binding and neutralization characteristics.

    Results: We were able to isolate over 40 mAbs from 2 BG505 SOSIP immunized rhesus macaques over time with a diverse set of characteristics. Both neutralizing and non-neutralizing mAbs were isolated with some mAbs only able to bind the trimer and not gp120, and others both trimer and gp120. Epitope mapping and EM revealed several target epitopes, including the V3 and CD4bs for non-neutralizing antibodies and epitopes at sites were the glycan shield was incomplete as some glycans are missing on BG505.

    Conclusions: These results are complementary to mAbs isolated from BG505 immunized rabbits previously, showing additional sites of vulnerability on BG505. The knowledge obtained in this study will provide important information that will help design immunization strategies to broaden the response after vaccination.